Revision as of 00:11, 8 September 2025

Data for RiskOfNeverTakingHRTForMenopause

Fracture Data

Explanation:*

Long-term HRT—either estrogen-only or combined—was associated with lower fracture incidence compared to placebo. Estrogen-only: fracture incidence decreased from 141 to 92–113 per 1000 over ~7.1 years; combined HRT: from 111 to 79–96 per 1000 over ~5.6 years. - Source: [PubMed](https://pubmed.ncbi.nlm.nih.gov/28093732/?utm_source=chatgpt.com)

  RiskModel: RiskofNeverTakingHRT/Data:FractureRiskModel
    Content: 
FractureWithoutHRT = ColumnFractureWithoutHRT  
FractureWithHRT = ColumnFractureWithHRT  
FractureRiskReduction = FractureWithoutHRT - FractureWithHRT

Cardiovascular, Stroke, and VTE Data

Explanation:*

In WHI data, estrogen-progestin therapy was associated with small increases in cardiovascular events: CHD (25 more per 10,000), stroke (12 more), and VTE (18 more). - Source: [CMAJ](https://www.cmaj.ca/content/170/10/1535?utm_source=chatgpt.com)

<RiskModel name="CardiovascularRiskModel"> CHD_WithHRT = ColumnWithHRT[Coronary heart disease] CHD_WithoutHRT = ColumnWithoutHRT[Coronary heart disease] Stroke_Wi_

@@ Line 7: / Line 7: @@
 </head>
 <row>
-“7.1 years—oestrogen‑only HT: 92–113 per 1000; placebo: 141 per 1000”
+.1 years—oestrogen-only | 92–113 per 1000 | 141 per 1000
 </row>
 <row>
-“5.6 years—combined HT: 79–96 per 1000; placebo: 111 per 1000”
+.6 years—combined HRT | 79–96 per 1000 | 111 per 1000
 </row>
 </datatable2>
-*Explanation:* Long‑term HRT—either estrogen‑only or combined—was associated with lower fracture incidence compared to placebo. Estrogen‑only: fracture incidence decreased from 141 to 92–113 per 1000 over ~7.1 years; combined HT: from 111 to 79–96 per 1000 over ~5.6 years.
+*Explanation:*
-- Source: WHI/IARC data on HRT fracture outcomes :contentReference[oaicite:0]{index=0}.
+Long-term HRT—either estrogen-only or combined—was associated with lower fracture incidence compared to placebo. Estrogen-only: fracture incidence decreased from 141 to 92–113 per 1000 over ~7.1 years; combined HRT: from 111 to 79–96 per 1000 over ~5.6 years.
+- Source: [PubMed](https://pubmed.ncbi.nlm.nih.gov/28093732/?utm_source=chatgpt.com)
-<RiskModel FractureRiskModel>
+<RiskModel name="FractureRiskModel">
-RiskWithoutHRT = ColumnFractureWithoutHRT
+FractureWithoutHRT = ColumnFractureWithoutHRT
-RiskWithHRT = ColumnFractureWithHRT
+FractureWithHRT = ColumnFractureWithHRT
-RiskDifference = RiskWithoutHRT – RiskWithHRT
+FractureRiskReduction = FractureWithoutHRT - FractureWithHRT
 </RiskModel>
@@ Line 29: / Line 30: @@
 </head>
 <row>
-“Estrogen‑progestin: +25 coronary events per 10 000 person‑years (157 vs 132)”
+Coronary heart disease | 157 per 10,000 | 132 per 10,000
 </row>
 <row>
-“Estrogen‑only: +12 strokes per 10 000 person‑years”
+Stroke | 44 per 10,000 | 32 per 10,000
 </row>
 <row>
-“Estrogen‑only: +7 thromboembolic events per 10 000 person‑years”
+Venous thromboembolism (VTE) | 34 per 10,000 | 16 per 10,000
 </row>
 </datatable2>
-*Explanation:* In the estrogen‑progestin arm, coronary events increased by 25 per 10,000 person‑years. In the estrogen‑only arm, there were 12 additional strokes and 7 additional venous thromboembolic events per 10,000 person‑years.
+*Explanation:*
-- Source: WHI data summarized by Canadian Task Force :contentReference[oaicite:1]{index=1}.
+In WHI data, estrogen-progestin therapy was associated with small increases in cardiovascular events: CHD (25 more per 10,000), stroke (12 more), and VTE (18 more).
+- Source: [CMAJ](https://www.cmaj.ca/content/170/10/1535?utm_source=chatgpt.com)
-<RiskModel CardiovascularRiskModel>
+<RiskModel name="CardiovascularRiskModel">
-RiskWithoutHRT_CHD = baseline (not in table)
+CHD_WithHRT = ColumnWithHRT[Coronary heart disease]
-RiskWithHRT_CHD = baseline + 25 per 10 000
+CHD_WithoutHRT = ColumnWithoutHRT[Coronary heart disease]
-RiskWithoutHRT_Stroke = baseline
+Stroke_Wi_
-RiskWithHRT_Stroke = baseline + 12 per 10 000
-RiskWithoutHRT_VTE = baseline
-RiskWithHRT_VTE = baseline + 7 per 10 000
-</RiskModel>
-== Breast Cancer Data ==
-<datatable2 name="CancerRiskTable">
-<head>
-ColumnWithHRT | ColumnExtraBreastCancerPer
-</head>
-<row>
-“9 additional breast cancers per 10 000 women with estrogen‑progestin for ≥5 years”
-</row>
-</datatable2>
-*Explanation:* Long‑term combined estrogen‑progestin HRT was associated with ~9 extra breast cancer cases per 10,000 women over 5 years.
-- Source: WHI breast cancer risk data :contentReference[oaicite:2]{index=2}.
-<RiskModel CancerRiskModel>
-BaselineBreastRisk = baseline (not in table)
-BreastRiskWithHRT = BaselineBreastRisk + ColumnExtraBreastCancerPer
-Difference = BreastRiskWithHRT – BaselineBreastRisk
-</RiskModel>
-== Dementia Data ==
-<datatable2 name="DementiaRiskTable">
-<head>
-ColumnOutcome | ColumnWithHRT | ColumnWithoutHRT
-</head>
-<row>
-“Dementia (≥65 yrs, combined HT 4 yrs): 11 vs 9 per 1000”
-</row>
-</datatable2>
-*Explanation:* Among women aged 65 and older, combined HRT for ~4 years raised dementia incidence from 9 to 11 per 1000 per year—i.e., ~2 additional cases per 1000 per year.
-- Source: WHI dementia outcomes :contentReference[oaicite:3]{index=3}.
-<RiskModel DementiaRiskModel>
-RiskWithoutHRT_Dementia = ColumnWithoutHRT
-RiskWithHRT_Dementia = ColumnWithHRT
-RiskDifference = RiskWithHRT_Dementia – RiskWithoutHRT_Dementia
-</RiskModel>
-== Uncertainty Note ==
-Risks are based on population averages. Individual outcomes may vary depending on age, health status, type/formulation of HRT, and geographic or demographic factors.
-Generated by an AI assistant.